Advertisement

A Mediterranean-style, low–glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome

Published:September 26, 2011DOI:https://doi.org/10.1016/j.metabol.2011.07.013

      Abstract

      The objective was to assess the impact of a Mediterranean-style, low–glycemic-load diet (control group, n = 41) and the same diet plus a medical food (MF) containing phytosterols, soy protein, and extracts from hops and Acacia (MF group, n = 42) on lipoprotein atherogenicity in women with metabolic syndrome. Plasma lipids, apolipoproteins (apos), lipoprotein subfractions and particle size, low-density lipoprotein (LDL) oxidation, and lipoprotein (a) were measured at baseline, week 8, and week 12 of the intervention. Three-day dietary records were collected at the same time points to assess compliance. Compared with baseline, women decreased energy intake from carbohydrate (P < .001) and fat (P < .001), whereas they increased energy intake from protein (P < .001). A significant increase in energy from monounsaturated fatty acids was also observed as well as increases in eicosapentaenoic acid and docosahexaenoic acid, whereas trans-fatty acid intake was reduced (P < .00001). The atherogenic lipoproteins, large very low-density lipoprotein (P < .0001) and small LDL (P < .0001), were reduced, whereas the ratio of large high-density lipoprotein to smaller high-density lipoprotein particles was increased (P < .0001). Apolipoprotein B was reduced for all women (P < .0001), with a greater reduction in the MF group (P < .025). Oxidized LDL (P < .05) and lipoprotein (a) (P < .001) were reduced in both groups at the end of the intervention. Consumption of a Mediterranean-style diet reduces the risk for cardiovascular disease by decreasing atherogenic lipoproteins, oxidized LDL, and apo B. Inclusion of an MF may have an additional effect in reducing apo B.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Flegal K.M.
        • Carroll M.D.
        • Ogden C.L.
        • et al.
        Prevalence and trends in obesity among us adults, 1999-2008.
        JAMA. 2010; 303: 235-241
        • Grundy S.M.
        • Brewer Jr., H.B.
        • Cleeman J.I.
        • et al.
        Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
        Circulation. 2004; 109: 433-438
        • Lyssenko V.
        • Sjögren M.
        • Almgren P.
        • et al.
        Genetic prediction of the metabolic syndrome.
        Diabetes Metab Syndr. 2008; 2: 245-252
        • Grundy S.M.
        • Cleeman J.I.
        • Daniels S.R.
        • et al.
        Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
        Circulation. 2005; 112: 2735-2752
        • Djoussé L.
        • Padilla H.
        • Nelson T.L.
        • et al.
        Diet and metabolic syndrome.
        Endocr Metab Immune Disord Drug Targets. 2010; 10: 124-137
        • Karampola M.
        • Papandreou D.
        • Makedou K.
        The role of Mediterranean diet in health and disease: an updated mini review.
        Nutr Food Sci. 2011; 41: 63-72
        • Babio N.
        • Bulló M.
        • Basora J.
        • et al.
        Adherence to the Mediterranean diet and risk of metabolic syndrome and its components.
        Nutr Metab Cardiovasc Dis. 2009; 19: 563-570
        • Saura-Calixto F.
        • Goni I.
        Definition of the Mediterranean diet based on bioactive compounds.
        Crit Rev Food Sci Nutr. 2009; 49: 145-152
        • Vaverkova H.
        LDL-C or apo B as the best target for reducing coronary heart disease: should apo B be implemented into clinical practice?.
        Clin Lipidol. 2011; 6: 35-48
        • Tziomalos K.
        • Athyros V.G.
        • Karagiannis A.
        • et al.
        Apolipoproteins C-II and C-III and small dense low density lipoprotein: novel risk factors in metabolic syndrome?.
        Arch Med Sci. 2008; 4: 270-273
        • Kypreos K.E.
        • Karagiannides I.
        • Fotiadou E.H.
        • et al.
        Mechanisms of obesity and related pathologies: role of apolipoprotein e in the development of obesity.
        FEBS J. 2009; 276: 5720-5728
        • Koba S.
        • Hirano T.
        • Ito Y.
        • et al.
        Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases.
        Atherosclerosis. 2006; 189: 206-214
        • Rizzo M.
        • Berneis K.
        Low-density lipoprotein size and cardiovascular risk assessment.
        QJM. 2006; 99: 1-14
        • Freedman D.S.
        • Otvos J.D.
        • Jeyarajah E.J.
        • et al.
        Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study.
        Clin Chem. 2004; 50: 1189-1200
        • Pascot A.
        • Lemieux I.
        • Prud'homme D.
        • et al.
        Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity.
        J Lipid Res. 2001; 42: 2007-2014
        • Onat A.
        • Hergenç G.
        • Özhan H.
        • et al.
        Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome.
        Coron Artery Dis. 2008; 19: 125-131
        • Holvoet P.
        • De Keyzer D.
        • Jacobs D.R.
        Oxidized LDL and the metabolic syndrome.
        Future Lipidol. 2008; 3: 637-649
        • Jones J.L.
        • Fernandez M.L.
        • McIntosh M.L.
        • et al.
        A Mediterranean-style low–glycemic-load diet improves variables of metabolic syndrome in women, and addition of a phytochemical-rich medical food enhances benefits on lipoprotein metabolism.
        J Clin Lipidol. 2011; 5: 188-196
      1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Schiltz B.
        • Minich D.M.
        • Lerman R.H.
        • et al.
        A science-based, clinically tested dietary approach for the metabolic syndrome.
        Metab Syndr Relat Disord. 2009; 7: 187-192
        • Liu M.Y.
        • Xydakis A.M.
        • Hoogeveen R.C.
        • et al.
        Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the luminex-100 system.
        Clin Chem. 2005; 51: 1102-1109
        • Liu S.
        • Willett W.C.
        • Stampfer M.J.
        • et al.
        A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in us women.
        Am J Clin Nutr. 2000; 71: 1455-1461
        • Shikany J.M.
        • Tinker L.F.
        • Neuhouser M.L.
        • et al.
        Association of glycemic load with cardiovascular disease risk factors: the Women's Health Initiative Observational Study.
        Nutrition. 2010; 26: 641-647
        • Levitan E.B.
        • Cook N.R.
        • Stampfer M.J.
        • et al.
        Dietary glycemic index, dietary glycemic load, blood lipids, and C-reactive protein.
        Metabolism. 2008; 57: 437-443
        • Klemsdal T.O.
        • Holme I.
        • Nerland H.
        • et al.
        Effects of a low glycemic load diet versus a low-fat diet in subjects with and without the metabolic syndrome.
        Nutr Metab Cardiovasc Dis. 2010; 20: 195-201
        • Kastorini C.M.
        • Milionis H.J.
        • Esposito K.
        • et al.
        The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals.
        J Am Coll Cardiol. 2011; 57: 1299-1313
        • Hu F.B.
        • Manson J.E.
        • Willett W.C.
        Types of dietary fat and risk of coronary heart disease: a critical review.
        J Am Coll Nutr. 2001; 20: 5-19
        • Gillingham L.G.
        • Harris-Janz S.
        • Jones P.J.H.
        Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors.
        Lipids. 2011; : 1-20
        • Berglund L.
        • Lefevre M.
        • Ginsberg H.N.
        • et al.
        Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states.
        Am J Clin Nutr. 2007; 86: 1611-1620
        • Tai C.C.
        • Ding S.T.
        N-3 polyunsaturated fatty acids regulate lipid metabolism through several inflammation mediators: mechanisms and implications for obesity prevention.
        J Nutr Biochem. 2010; 21: 357-363
        • Zuliani G.
        • Galvani M.
        • Leitersdorf E.
        • et al.
        The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias.
        Curr Pharm Des. 2009; 15: 4087-4093
        • Cicero A.F.G.
        • Ertek S.
        • Borghi C.
        Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management.
        Curr Vasc Pharmacol. 2009; 7: 330-337
        • Berneis K.K.
        • Krauss R.M.
        Metabolic origins and clinical significance of LDL heterogeneity.
        J Lipid Res. 2002; 43: 1363-1379
        • Palmer A.M.
        • Nova E.
        • Anil E.
        • et al.
        Differential uptake of subfractions of triglyceride-rich lipoproteins by THP-1 macrophages.
        Atherosclerosis. 2005; 180: 233-244
        • Zambon A.
        • Bertocco S.
        • Vitturi N.
        • et al.
        Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.
        Biochem Soc Trans. 2003; 31: 1070-1074
        • Julius U.
        • Dittrich M.
        • Pietzsch J.
        Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance.
        Int J Clin Pract. 2007; 61: 1798-1804
        • Rizzo M.
        • Berneis K.
        Small, dense low-density-lipoproteins and the metabolic syndorme.
        Diabetes Metab Res Rev. 2007; 23: 14-20
        • Volek J.S.
        • Fernandez M.L.
        • Feinman R.D.
        • et al.
        Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome.
        Prog Lipid Res. 2008; 47: 307-318
        • El Harchaoui K.
        • Arsenault B.J.
        • Franssen R.
        • et al.
        High-density lipoprotein particle size and concentration and coronary risk.
        Ann Intern Med. 2009; 150: 84-93
        • de Souza J.A.
        • Vindis C.
        • Hansel B.
        • et al.
        Metabolic syndrome features small, apolipoprotein A-I–poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity.
        Atherosclerosis. 2008; 197: 84-94
        • Sima A.
        • Iordan A.
        • Stancu C.
        Apolipoprotein E polymorphism—a risk factor for metabolic syndrome.
        Clin Chem Lab Med. 2007; 45: 1149-1153
        • Contois J.H.
        • McConnell J.P.
        • Sethi A.A.
        • et al.
        Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.
        Clin Chem. 2009; 55: 407-419
        • Tailleux A.
        • Duriez P.
        • Fruchart J.C.
        • et al.
        Apolipoprotein A-II, HDL metabolism and atherosclerosis.
        Atherosclerosis. 2002; 164: 1-13
        • Holvoet P.
        • Lee D.H.
        • Steffes M.
        • et al.
        Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome.
        JAMA. 2008; 299: 2287-2293
        • Fitó M.
        • Guxens M.
        • Corella D.
        • et al.
        Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial.
        Arch Intern Med. 2007; 167: 1195-1203
        • Raederstorff D.
        Antioxidant activity of olive polyphenols in humans: a review.
        Int J Vitam Nutr Res. 2009; 79: 152-165
        • Galvano F.
        • Malaguarnera M.
        • Vacante M.
        • et al.
        The physiopathology of lipoprotein (a).
        Front Biosci (Scholar edition). 2010; 2: 866-875
        • Bermúdez V.
        • Arráiz N.
        • Aparicio D.
        • et al.
        Lipoprotein(a): from molecules to therapeutics.
        Am J Ther. 2010; 17: 263-273
        • Ramsden C.E.
        • Faurot K.R.
        • Carrera-Bastos P.
        • et al.
        Dietary fat quality and coronary heart disease prevention: a unified theory based on evolutionary, historical, global, and modern perspectives.
        Curr Treat Options Cardiovasc Med. 2009; 11: 289-301